Long-term outcomes of high-dose hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer.
Concurrent chemoradiotherapy with thoracic radiotherapy of 45 Gy in 30 twice-daily fractions is the standard treatment for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal thoracic radiotherapy dose remains uncertain. This study aimed to evaluate the efficacy and safety of high-dose hyperfractionate...